The study was retrospective, relied on structured EHR data, and used coded definitions for recurrence rather than centrally adjudicated oncologic outcomes
You dont need to train like an athlete
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Vegetarians and vegans who do not consume these foods may have a higher risk of L-Carnitine deficiency
Discover how BPC-157 heals IBS, IBD & leaky gut in 8-12 weeks